+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 3Months - 47Months
All Genders
ID07536269

Evaluating Safety and Effects of Oral Crinecerfont in Children Under 4 Years With Classic Congenital Adrenal Hyperplasia

Led by Neurocrine Switzerland GmbH · Updated on 2026-09-16

20

Participants Needed

11

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of crinecerfont in young children aged from 3 months to under 4 years who have classic congenital adrenal hyperplasia CAH. This study focuses on pediatric participants diagnosed with classic CAH caused by 21-hydroxylase deficiency, aiming to understand how this drug behaves and is processed in their bodies. Participants will receive crinecerfont as an oral solution. The study is open-label and includes only one group receiving this experimental drug. The treatment period lasts up to 28 weeks, during which the researchers will monitor safety and any side effects. Throughout the study, participants will be assessed for treatment-emergent adverse events from the first day up to 28 weeks. The study includes monitoring of drug effects and tolerability in this young population. Participants are expected to have stable hydrocortisone treatment before joining, and the study will continue until March 2028.

CONDITIONS

Brief Title

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Research Team

N

Neurocrine Medical Information Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here